Evaluation of cardiac sympathetic nervous function by 123I-metaiodobenzylguanidine scintigraphy in insulin-treated non-insulin dependent diabetics with hypoglycemia unawareness

Internal Medicine

Volumn 35, Issue 2, 1996, Pages 94-99

  Ohno, Tomio ^a,b   Toyama, Takuji ^a   Hoshizaki, Hiroshi ^a   Okamoto, Eiichi ^a   Naito, Shigeto ^a   Nogami, Akihiko ^a   Kamiyama, Hiroshi ^a   Ohshima, Shigeru ^a   Yuasa, Kazuo ^a   Taniguchi, Koichi ^a   Tomono, Shoichi ^b   Kawazu, Shoji ^b  

^a GUNMA PREFECTURAL CARDIOVASCULAR CENTER   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Autonomic neuropathy; Catecholamine; Insulin induced hypoglycemia; Myocardial scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CATECHOLAMINE; INSULIN; IODINE 123;

ARTICLE; CLINICAL ARTICLE; FUNCTION TEST; HEART FUNCTION; HEART RATE; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; SCINTIGRAPHY; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE;

3-IODOBENZYLGUANIDINE; DIABETES MELLITUS, TYPE 2; EPINEPHRINE; HEART; HEART FUNCTION TESTS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENOUS; INSULIN; IODINE RADIOISOTOPES; IODOBENZENES; MIDDLE AGED; NOREPINEPHRINE; PERCEPTION; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS;

EID: 0029972617     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.35.94     Document Type: Article

References (17)

1. Hoeldtke RD, Boden G, Shuman CR, Owen OE. Reduced epinephrine secretion and hypoglycemia unawareness in diabetic autonomic neuropathy. Ann Intern Med 96: 459, 1982.
2. Adamson U, Lins PE, Efendic S, Hamberger B, Wajngot A. Impaired counter regulation of hypoglycemia in a group of insulin-dependent diabetics with recurrent episodes of severe hypoglycemia. Acta Med Scand 216: 215, 1984.
3. Heller SR, Macdonald IA, Herbert M, Tattersall RB. Influence of sympathetic nervous system on hypoglycaemic warning symptoms. Lancet 2: 359, 1987.
4. Cryer PE. Glucose counterregulation in man. Diabetes 30: 261, 1981.
5. Gerich JE, Mokan M, Veneman T, Korytkowski M, Mitrakou A. Hypoglycemia unawareness. Endocr Rev 12: 356, 1991.
6. 131I]iodobenzylguanidine. J Nucl Med 21: 349, 1980.
7. Kline RC, Swanson DP, Wieland DM, et al. Myocardial imaging in man with I-123 metaiodobenzylguanidine. J Nucl Med 22: 129, 1981.
8. Sisson JC, Shapiro B, Meyers L, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 28: 1625, 1987.
9. 123I metaiodobenzylguanidine. Diabetes 41: 1069, 1992.
10. 123I iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM Comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes 44: 543, 1995.
11. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33: 471, 1992.
12. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 78: 1192, 1988.
13. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 12: 1252, 1988.
14. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 8: 491, 1985.
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977, 1993.
16. Awareness of hypoglycemia in diabetes. Lancet 2: 371, 1987 (editorial).
17. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycaemia in 411 type I diabetic patients. Diabetic Med 8: 217, 1991.